Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (31-40 of 226) with videos related to

Pageof 23
Sort By:
Immunotherapy|May 7, 2010
Inhibitors of B7-CD28 costimulation in urologic malignanciesR Houston Thompson, Eugene D Kwon, James P Allison
Advances in Immunology|May 30, 2006
Checkpoint blockade in cancer immunotherapyAlan J Korman, Karl S Peggs, James P Allison
Nature Immunology|June 28, 2002
CTLA-4: new insights into its biological function and use in tumor immunotherapyJackson G Egen, Michael S Kuhns, James P Allison
Cancer Discovery|August 18, 2018
Fundamental Mechanisms of Immune Checkpoint Blockade TherapySpencer C Wei, Colm R Duffy, James P Allison
Urologic Oncology|September 12, 2006
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancerR Houston Thompson, James P Allison, Eugene D Kwon
The Journal of Experimental Medicine|July 6, 2011
Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunityJoyce Wei, P'ng Loke, Xingxing Zang, et al.
Cancer Cell|September 6, 2007
Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negativeKarl S Peggs, Neil H Segal, James P Allison
Seminars in Oncology|November 16, 2010
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapyMargaret K Callahan, Jedd D Wolchok, James P Allison
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2006
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanismJohn J Engelhardt, Timothy J Sullivan, James P Allison
Immunological Reviews|September 2, 2008
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapyKarl S Peggs, Sergio A Quezada, James P Allison
Pageof 23

Showing results (31-40 of 226) with videos related to

Sort By:
Pageof 23
Immunotherapy|May 7, 2010
Inhibitors of B7-CD28 costimulation in urologic malignanciesR Houston Thompson, Eugene D Kwon, James P Allison
Advances in Immunology|May 30, 2006
Checkpoint blockade in cancer immunotherapyAlan J Korman, Karl S Peggs, James P Allison
Nature Immunology|June 28, 2002
CTLA-4: new insights into its biological function and use in tumor immunotherapyJackson G Egen, Michael S Kuhns, James P Allison
Cancer Discovery|August 18, 2018
Fundamental Mechanisms of Immune Checkpoint Blockade TherapySpencer C Wei, Colm R Duffy, James P Allison
Urologic Oncology|September 12, 2006
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancerR Houston Thompson, James P Allison, Eugene D Kwon
The Journal of Experimental Medicine|July 6, 2011
Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunityJoyce Wei, P'ng Loke, Xingxing Zang, et al.
Cancer Cell|September 6, 2007
Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negativeKarl S Peggs, Neil H Segal, James P Allison
Seminars in Oncology|November 16, 2010
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapyMargaret K Callahan, Jedd D Wolchok, James P Allison
Journal of Immunology (Baltimore, Md. : 1950)|July 5, 2006
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanismJohn J Engelhardt, Timothy J Sullivan, James P Allison
Immunological Reviews|September 2, 2008
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapyKarl S Peggs, Sergio A Quezada, James P Allison
Pageof 23